ATRA
Price
$7.95
Change
+$0.23 (+2.98%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
45.96M
BLUE
Price
$4.97
Change
-$0.00 (-0.00%)
Updated
May 30 closing price
Capitalization
48.67M
Interact to see
Advertisement

ATRA vs BLUE

Header iconATRA vs BLUE Comparison
Open Charts ATRA vs BLUEBanner chart's image
Atara Biotherapeutics
Price$7.95
Change+$0.23 (+2.98%)
Volume$100
Capitalization45.96M
bluebird bio
Price$4.97
Change-$0.00 (-0.00%)
Volume$1.25M
Capitalization48.67M
ATRA vs BLUE Comparison Chart in %
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. BLUE commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Buy and BLUE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (ATRA: $7.72 vs. BLUE: $4.97)
Brand notoriety: ATRA and BLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 34% vs. BLUE: 117%
Market capitalization -- ATRA: $45.96M vs. BLUE: $48.67M
ATRA [@Biotechnology] is valued at $45.96M. BLUE’s [@Biotechnology] market capitalization is $48.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileBLUE’s FA Score has 1 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • BLUE’s FA Score: 1 green, 4 red.
According to our system of comparison, BLUE is a better buy in the long-term than ATRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 3 TA indicator(s) are bullish.

  • ATRA’s TA Score: 3 bullish, 5 bearish.

Price Growth

ATRA (@Biotechnology) experienced а -2.03% price change this week, while BLUE (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

ATRA is expected to report earnings on May 15, 2025.

BLUE is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BLUE($48.7M) has a higher market cap than ATRA($46M). BLUE (-40.408) and ATRA (-41.998) have similar YTD gains . ATRA has higher annual earnings (EBITDA): -5.74M vs. BLUE (-215.81M). BLUE has more cash in the bank: 70.7M vs. ATRA (13.8M). ATRA has less debt than BLUE: ATRA (40.6M) vs BLUE (368M). ATRA has higher revenues than BLUE: ATRA (200M) vs BLUE (53.1M).
ATRABLUEATRA / BLUE
Capitalization46M48.7M94%
EBITDA-5.74M-215.81M3%
Gain YTD-41.998-40.408104%
P/E RatioN/AN/A-
Revenue200M53.1M377%
Total Cash13.8M70.7M20%
Total Debt40.6M368M11%
FUNDAMENTALS RATINGS
ATRA vs BLUE: Fundamental Ratings
ATRA
BLUE
OUTLOOK RATING
1..100
7136
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BLUE's Valuation (21) in the Biotechnology industry is somewhat better than the same rating for ATRA (75). This means that BLUE’s stock grew somewhat faster than ATRA’s over the last 12 months.

BLUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that BLUE’s stock grew similarly to ATRA’s over the last 12 months.

BLUE's SMR Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that BLUE’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (55) in the Biotechnology industry is in the same range as BLUE (64). This means that ATRA’s stock grew similarly to BLUE’s over the last 12 months.

ATRA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BLUE (100). This means that ATRA’s stock grew similarly to BLUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRA
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 23 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SOPH3.100.01
+0.32%
SOPHiA GENETICS SA
EQNR25.140.03
+0.12%
Equinor ASA
HOG23.60-0.02
-0.08%
Harley-Davidson
VRE14.89-0.02
-0.13%
Veris Residential
APLT0.31-0.01
-3.92%
Applied Therapeutics

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been closely correlated with IKNA. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if ATRA jumps, then IKNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
-2.89%
IKNA - ATRA
72%
Closely correlated
-1.47%
ABCZF - ATRA
53%
Loosely correlated
N/A
RAPT - ATRA
37%
Loosely correlated
-5.10%
PHAT - ATRA
36%
Loosely correlated
-1.54%
LENZ - ATRA
33%
Loosely correlated
-2.79%
More